Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-Parkinsonian rats

被引:11
作者
Glavan, G [1 ]
Sket, D [1 ]
Zivin, M [1 ]
机构
[1] Univ Ljubljana, Sch Med, Inst Pathophysiol, Brain Res Lab, Ljubljana 1000, Slovenia
关键词
D O I
10.1124/mol.61.2.360
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Parkinsonism, a common unwanted side effect of typical antipsychotic (neuroleptic) drugs, is induced by the blockade of striatal dopamine D2 receptors. In rats with hemi-parkinsonism induced by unilateral lesion of dopaminergic nigrostriatal neurons with 6-hydroxydopamine, D2 antagonists inhibit contralateral turning induced by D2 agonists and augment the levels of neurotensin mRNA in dopaminergically intact striatum. By contrast, D1 agonists induce contralateral turning and augment neurotensin mRNA levels in dopamine-depleted striatum. These effects could be inhibited by D1 but not by D2 antagonists. Here we used a hemi-parkinsonian model to investigate the effects of putative D1 agonist/D2 antagonist LEK-8829 (9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate), an experimental antipsychotic, on turning behavior and the expression of striatal neurotensin, preprotachykinin and neurotransmitter-induced early gene protein 4 (ania-4) mRNAs. We found that LEK-8829 inhibited contralateral turning induced by D2 agonist quinpirole, but only if the rats were cotreated with D1 antagonist SCH-23390. In situ hybridization showed that LEK-8829 induced the expression of neurotensin and ania-4 mRNAs in dopamine-intact striatum that could be completely blocked only by the combined treatment with SCH-23390 and quinpirole. In addition, LEK-8829 augmented the expression of neurotensin, preprotachykinin and ania-4 mRNAs in dopamine-depleted striatum that could be completely blocked by SCH-23390. This study clearly demonstrates that in hemi-parkinsonian rats D1 agonistic activity of LEK-8829 confers its anti-parkinsonian drug-like properties and modulates its neuroleptic drug-like properties, which are dependent on the blockade of dopamine D2 receptors. These findings imply that atypical antipsychotics with D1 intrinsic activity might have a reduced propensity for the induction of extrapyramidal syndrome.
引用
收藏
页码:360 / 368
页数:9
相关论文
共 29 条
[1]   Clozapine:: Dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a rosetta stone of antipsychotic drugs [J].
Ahlenius, S .
PHARMACOLOGY & TOXICOLOGY, 1999, 84 (05) :193-196
[2]  
[Anonymous], RAT BRAIN STEREOTAXI
[3]   A complex program of striatal gene expression induced by dopaminergic stimulation [J].
Berke, JD ;
Paletzki, RF ;
Aronson, GJ ;
Hyman, SE ;
Gerfen, CR .
JOURNAL OF NEUROSCIENCE, 1998, 18 (14) :5301-5310
[4]   Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats [J].
Bordet, R ;
Ridray, S ;
Schwartz, JC ;
Sokoloff, P .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (06) :2117-2123
[5]   Interactions between D1 and D2 dopamine receptor family agonists and antagonists: The effects of chronic exposure on behavior and receptor binding in rats and their clinical implications [J].
Braun, AR ;
Laruelle, M ;
Mouradian, MM .
JOURNAL OF NEURAL TRANSMISSION, 1997, 104 (4-5) :341-362
[6]   THE NEUROLEPTICS - A HISTORICAL SURVEY [J].
DENIKER, P .
ACTA PSYCHIATRICA SCANDINAVICA, 1990, 82 :83-87
[7]   D1 AND D2 DOPAMINE RECEPTOR REGULATED GENE-EXPRESSION OF STRIATONIGRAL AND STRIATOPALLIDAL NEURONS [J].
GERFEN, CR ;
ENGBER, TM ;
MAHAN, LC ;
SUSEL, Z ;
CHASE, TN ;
MONSMA, FJ ;
SIBLEY, DR .
SCIENCE, 1990, 250 (4986) :1429-1432
[8]   Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion [J].
Granata, R ;
Wenning, GK ;
Jolkkonen, J ;
Jenner, P ;
Marsden, CD .
JOURNAL OF NEURAL TRANSMISSION, 1996, 103 (03) :249-260
[9]   Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway [J].
Hanson, GR ;
Keefe, KA .
MOLECULAR BRAIN RESEARCH, 1999, 66 (1-2) :111-121
[10]  
HAVERSTICK DM, 1989, J PHARMACOL EXP THER, V248, P858